The association between clinician-based common terminology criteria for adverse events (CTCAE) and patient-reported outcomes (PRO): a systematic review by Atkinson, Thomas M. et al.
The Association between Clinician-Based Common Terminology 
Criteria for Adverse Events (CTCAE) and Patient-Reported 
Outcomes (PRO): A Systematic Review
Thomas M. Atkinson, Ph.D.1, Sean J. Ryan, M.A.1,2, Antonia V. Bennett, Ph.D.3, Angela M. 
Stover, Ph.D.3, Rebecca M. Saracino, MA1, Lauren J. Rogak, MA1, Sarah T. Jewell, MLS5, 
Konstantina Matsoukas, MLS1, Yuelin Li, PhD1, and Ethan Basch, MD, MPh1,3
1Memorial Sloan Kettering Cancer Center, New York, NY, USA
2City University of New York, New York, NY, USA
3University of North Carolina at Chapel Hill, Chapel Hill, NC, USA
5Rutgers, The State University of New Jersey, Newark, NJ, USA
Abstract
 Purpose—Symptomatic adverse events (AEs) are monitored by clinicians as part of all US-
based clinical trials in cancer via the U.S. National Cancer Institute’s Common Terminology 
Criteria for Adverse Events (CTCAE) for the purposes of ensuring patient safety. Recently there 
has been a charge toward capturing the patient perspective for those AEs amenable to patient self-
reporting via patient-reported outcomes (PRO). The aim of this review was to summarize the 
empirically reported association between analogous CTCAE and PRO ratings.
 Methods—A systematic literature search was conducted using PubMed, EMBASE, Web of 
Science, and Cochrane databases through July 2015. From a total of 5,658 articles retrieved, 28 
studies met inclusion criteria.
 Results—Across studies, patients were of mixed cancer types, including anal, breast, cervical, 
chronic myeloid leukemia, endometrial, hematological, lung, ovarian, pelvic, pharyngeal, prostate 
and rectal. Given this mixture, the AEs captured were variable, with many common across studies 
(e.g., dyspnea, fatigue, nausea, neuropathy, pain, vomiting), as well as several that were disease-
specific (e.g., erectile dysfunction, hemoptysis). Overall, the quantified association between 
CTCAE and PRO ratings fell in the fair to moderate range and had large variation across the 
majority of studies (n = 21).
 Conclusions—The range of measures used and symptoms captured varied greatly across the 
reviewed studies. Regardless of concordance metric employed, reported agreement between 
CTCAE and PRO ratings was moderate at best. To assist with reconciliation and interpretation of 
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these differences toward ultimately improving patient care, an important next step is to explore 
approaches to integrate PROs with clinician reporting of AEs.
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Drug Monitoring; Drug-Related Side Effects and Adverse Reactions; Literature Review; 
Neoplasms; Self Report; Toxicity
 INTRODUCTION
Accurate monitoring of symptomatic adverse events (AEs) is essential in clinical trials to 
assess and ensure patient safety, as well as inform decisions related to treatment and/or 
continued trial participation [1, 2]. Standard documentation of this information in United 
States-based cancer clinical trials has relied solely on clinician reporting using an AE rating 
system known as the Common Terminology Criteria for Adverse Events (CTCAE) [3]. This 
library of descriptive terms was developed and is maintained by the United States National 
Cancer Institute (NCI) and consists of 790 items that capture information on discrete events; 
each is graded by a clinician on a 5-point scale. Of these, 78 items have been identified as 
objective, observable AEs [4].
Recently, there has been a charge toward the use of patient-reported outcomes (PROs), 
defined as the unfiltered direct report of a given symptom toxicity by a patient, and 
considered to be the “gold standard” for the capture of symptomatic AEs [5, 6]. This charge 
has been led by the release of the 2009 United States Food and Drug Administration (FDA) 
Guidance for Industry on the Use of PRO Measures in Medical Development to Support 
Labeling Claims [7], which subsequently led to the NCI initiative to develop a PRO version 
of the CTCAE (PRO-CTCAE) that will be used in future U.S.-based clinical trials in 
oncology [4, 8, 9].
As the integration of PRO symptomatic AE ratings into cancer clinical trials becomes 
commonplace, it is important to understand the degree to which this patient-driven 
information is complementary to clinician-based CTCAE ratings of observable AEs. The 
purpose of this review is to summarize the current state of the literature with respect to 
characterizing the association between clinician-based CTCAE and patient-based PRO 
ratings.
 METHODS
 Search Strategy
A systematic search for articles published in peer-reviewed medical journals was conducted 
with assistance from health sciences librarians using PubMed, EMBASE, Web of Science, 
and Cochrane Central Register of Controlled Trials (CENTRAL) databases. In PubMed, 
Medical Subject Headings (MeSH) were used. In Embase, Emtree terms were exploded. The 
search terms were: ("Neoplasms"[Mesh] OR cancer OR cancers OR cancerous OR tumor 
OR tumors OR tumour OR tumours OR neoplasm* OR neoplastic OR malignan* OR 
metastatic OR metastasis OR metastases) AND (physician* OR doctor OR doctors OR 
clinician* OR "general practitioner" OR "general practitioners" OR provider* OR 
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specialist* OR nurse* OR staff OR oncologist*) AND (agreement OR disagreement OR 
reliability OR concordance OR discrepancy OR consistency OR consensus OR "intra-class 
correlation coefficient" OR "intraclass correlation coefficient" OR "kappa correlation" OR 
"kappa coefficient" OR “self assessment” OR “physician assessment” OR “provider 
assessment” OR “self assessed” OR “physician assessed” OR “provider assessed” OR 
“patient ratings” OR “physician ratings” OR “provider ratings” OR “patients rated” OR 
“physicians rated” OR “providers rated” OR "Physician's Role"[Mesh]) AND ("adverse 
symptom event" OR "adverse symptom events" OR "adverse event" OR "adverse events" 
OR "adverse effect" OR "adverse effects" OR "patient reported outcome" OR "quality of 
life" OR "Quality of Life"[Mesh] OR ECOG OR “Eastern Cooperative Oncology Group” 
OR “functional problems” OR distress OR “performance status” OR depression). There 
were no date or language restrictions; each database was search in its entirety, through July 
2015.
 Selection Strategy
We deemed studies were eligible for inclusion if they (1) made an original report of a 
quantitative comparison between analogous CTCAE and PRO ratings, and (2) included 
participants aged 18 or older.
 Screening Process
For the title screening, abstract review, and full-text review stages, two co-authors were 
randomly assigned to independently review each article for eligibility, with discrepancies 
arbitrated by a third co-author who was naïve to the article. At the full-text review stage, 
each assigned co-author completed standardized coding forms to extract the pre-determined 
data from the potentially eligible articles. References from the included full-text articles 
were searched to determine whether they should be also considered for inclusion. Study 
quality was assessed using a modified version of the Downs and Black Study Quality 
Checklist [10] (i.e., 16 of the original 27 quality indicators most relevant to the types of 
studies reviewed)=. Based on quality, an article was considered to be fit for inclusion if it 
met at least 33% of the modified Downs and Black Study quality indicators.
For the purposes of this review, cutoffs for all agreement metrics reported, including 
percentage agreement, Kendall-tau rank correlation (τ), Goodman and Kruskal’s gamma 
statistic (γ), Pearson correlation (r) , Cohen’s kappa (κ), weighted Cohen’s kappa (κw) 
statistics were defined as: poor (0.00–0.29), moderate (0.30–0.69), and strong (0.70–1.00). 
For instances where only specificity/sensitivity was reported, the following cutoffs were 
used: low (0.00–0.29), moderate (0.30–0.69), and high (0.70–1.00).
 RESULTS
A total of 7,474 titles were identified through electronic database searching, with 75 
additional records found through hand searching. After duplicates were removed, a total of 
5,658 articles were retrieved. Following title screening, 908 articles were identified for 
=Questions 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 16, 17, 18, 19, 20, and 26 from the Downs and Black Study Quality Checklist were used to 
assess quality.
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abstract review with 93.6% agreement between the independent pairs of raters. A total of 
251 full-text articles were reviewed. Reasons for article exclusion during the full-text review 
included: CTCAE not used (n = 161), PROs were not assessed (n = 18), the article was a 
review or did not include original research findings (n = 18), CTCAE and PRO ratings were 
not explicitly compared (n = 12), and the article described a non-cancer population (n = 5). 
Twenty-eight articles met eligibility criteria and were included in this review (Figure 1). 
Each of these articles possessed at least 47% of the relevant quality indicators from a 
modified version of the Downs and Black Study Quality Checklist [10], with 21 of the 
included articles having 75% or more of these quality indicators.
 Study Characteristics
Table 1 provides a summary of clinical characteristics and findings from each of the 28 
included studies. Patients were of mixed cancer types, including anal, breast, cervical, 
chronic myeloid leukemia, endometrial, hematological, lung, ovarian, pelvic, pharyngeal, 
prostate and rectal. Given this, the AEs captured were variable, with many common across 
studies (e.g., dyspnea, fatigue, nausea, neuropathy, pain, vomiting), as well as several that 
were disease-specific (e.g., erectile dysfunction, hemoptysis, xerostomia).
Well-validated PRO measures were used to capture patient-based AE ratings in 20 of the 
included studies. This included disease specific modules of the European Organization for 
Research and Treatment of Cancer (EORTC) [12–20] and Functional Assessment of Cancer 
Therapy (FACT) [21–23] instruments, as well as the dermatology-specific Skindex-16, [24, 
25] the EuroQol EQ-5D, [26] the Short-Form 36 Health Survey (SF-36) [27], and two 
recently developed bowel symptom inventories [28, 29]. Patient-adapted versions of the 
CTCAE were used in four studies [27, 30–32], with visual analog scales used to capture 
patient-rated AEs in three studies [11, 33, 34].
 Association between CTCAE and PRO Ratings
A poor to moderate association between CTCAE and PRO ratings was reported in the 
majority of included studies (n = 21). Seven such studies reported this as a general finding, 
with agreement statistics ranging from κ = 0.00 to r = 0.74 [14, 24, 27, 32, 34, 35]. 
Regardless of how pain was self-reported by patients (i.e., EuroQol EQ-5D or EORTC 
QLQ-C30), four independent studies reported moderate agreement between PRO and 
CTCAE ratings (r range = 0.33–0.37; κ range = 0.16–0.29) [16, 17, 20, 26]. Similarly, 
independent assessments of nausea and vomiting were reported as being poor, as captured 
by Symptom Tracking and Reporting (STAR) (τ = 0.11 and −0.02) [26] to moderate, as 
captured by EORTC QLQ-C30 (r range = 0.47–0.48, κ range = 0.41–0.48) [15–17].
Independent studies that made use of the Bowel Problem Scale in cohorts of patients with 
rectal [28] or anal [29] cancer found poor agreement with clinician ratings for proctitis (κ = 
0.22 and 0.11, respectively) and moderate agreement for diarrhea (κ = 0.64 and 0.68, 
respectively). Additionally, independent studies of neuropathy reported a poor to moderate 
relationship between PRO and CTCAE reports, as measured by the FACT Gynecologic 
Oncology Group – Neurotoxicity Module (FACT/GOG-Ntx) (r’s range 0.23–0.69) [23, 36]. 
A study that made use of the Patient Neurotoxicity Questionnaire found that patients more 
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frequently reported severe neuropathy (30%) as compared to that identified by CTCAE 
(10%) [37].
Several studies (n = 4) reported a mix of poor, moderate and strong associations between 
CTCAE and PRO ratings. In a study of 400 patients with lung or genitourinary cancer, 
Basch and colleagues [30] reported a strong percentage of agreement between CTCAE and a 
modified CTCAE for nausea and vomiting (96% and 90%, respectively), but relatively 
moderate percent agreement for fatigue (55%) and strong percent agreement for pain (70%). 
A study of 82 patients with lung cancer led by Brabo [13] observed a moderate correlation 
between CTCAE and the sore mouth (r = 0.41, p < 0.01), and alopecia items (r = 0.52, p < 
0.01) from EORTC QLQ-C30. However, strong correlations were observed when comparing 
CTCAE and the EORTC QLQ-C30 dysphagia (r = 0.73, p < 0.01) and neuropathy (r = 0.72, 
p < 0.01) items. As part of a study of 100 patients with mixed cancer types, Cirillo and 
colleagues [31] found moderate agreement between CTCAE and a modified patient CTCAE 
for asthenia (κ = 0.32, 95% Confidence Interval (CI): 0.17 to 0.44), but strong agreement 
between clinicians and patients for nausea (κ = 0.74, 95% CI: 0.64–0.85) and diarrhea (κ = 
0.71, 95% CI: 0.43–0.90). A recently completed study of 66 patients with lung cancer by 
Tang and colleagues [38] found poor agreement between CTCAE and the Thoracic 
Symptom Self-Assessment Tool (TSSAT) for nausea (κw = 0.07, 95% CI: −0.16–0.30) and 
insomnia (κw = 0.03, 95% CI: −0.34–0.39), but strong agreement for hemoptysis (κw = 0.71, 
95% CI: 0.35–1.00).
Three studies reported strong agreement between CTCAE and PRO ratings. This included a 
study of 281 patients with chemotherapy induced peripheral neuropathy, as captured by the 
EORTC QLQ-CIPN20 [12]; a study of edema, neuropathy and pain in 1031 patients with 
lung cancer, as captured by the FACT-Taxane module [22]; as well as a study of nausea in 30 
patients with mixed cancer types, as measured by a visual analogue scale (r = 0.88, p < 
0.001) [11].
 DISCUSSION
As the oncological clinical encounter increasingly incorporates patient-reported data, it is 
necessary to inform clinicians how this data relates to the standard AE ratings they have 
been making as part of clinical trials and their routine practice. This review demonstrated 
that, regardless of which self-report measure was used, the majority of studies that have 
directly compared CTCAE and PRO ratings report a poor to moderate association between 
clinician and patient-based AEs, either globally, or by individual symptom (e.g., nausea, 
neuropathy, pain, vomiting).
This discordance between clinicians and patients provides further evidence that PRO 
measures provide unique, valuable information that can be complementary to CTCAE 
ratings. For instance, in a systematic review completed by Gotay and colleagues, it was 
demonstrated that PRO measures are correlated with survival in cancer clinical trials and 
provide information above and beyond conventional clinical assessments [39].
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Currently, all AEs in clinical trials, including adverse symptoms, are documented by 
providers at clinic visits to meet federal requirements and facilitate evaluation of new 
therapies. Patient self-reporting has a relatively minimal role. However, this current practice 
is problematic, as our previous work has demonstrated that AEs frequently go undetected by 
clinicians or are reported as less severe than via patient reporting [26, 40]. Additionally, the 
CTCAE recall period encompasses the entire period since the last clinic visit for a given 
patient. In many cases, a patient follow-up visit might not occur for 2–4 weeks, which can 
lead to a loss of information related to AEs that are experienced early in that timeframe.
Recognizing the importance of accurately capturing the patient perspective as 
complementary information to clinician-based reporting, the NCI has developed a patient 
language version of the CTCAE (PRO-CTCAE) [4]. PRO-CTCAE is an electronic-based 
system for patient self-reporting of AEs from the CTCAE that were found to be amenable to 
patient reporting. This library of 78 symptoms was identified and developed via a process of 
direct cognitive interviews with patients and extensive quantitative validation in a large 
multicenter study [8, 9]. PRO-CTCAE utilizes a 7-day recall period and can be completed 
routinely by patients, and thus may be implemented to systematically capture AEs that may 
not apparent at the time of clinician-based CTCAE grading.
The present review is limited by a number of factors. The timing of the respective CTCAE 
and PRO ratings was not explicitly stated in the majority of included articles, though it was 
implied that these AEs were proximally assessed. Future studies should clearly indicate the 
amount of time that occurs between clinician- and patient-based AE reporting to eliminate 
the possibility that the level of agreement between these rating sources is being influenced 
by passage of time (e.g., separate visits, between visits versus next or previous clinic visit). 
Additionally, a meta-analysis would have been optimal to best characterize the relationship 
between CTCAE and PRO ratings. Unfortunately, given the variety of PRO measures used 
and numerous instances where study authors did not provide detailed statistical coefficient 
for each AE captured, a meta-analysis was infeasible.
To better assist clinicians with understanding the relationship between their CTCAE ratings 
and PRO assessments, future work should seek to systematically equate CTCAE and PRO 
ratings. Future approaches that aim to integrate PROs with clinician reporting of AEs, 
especially those of the CTCAE and PRO-CTCAE, would improve our understanding of 
patient and clinician ratings and assist clinicians and policy makers with the interpretation of 
clinical trial results.
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Figure 1. 
PRISMA Flow Chart
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